Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)
Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%
Abbott Laboratories operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Abbott Laboratories's operating cash flow for the twelve months ending Jun 30, 2026 was $9.91B, up 9.6% year over year. For fiscal 2025 it was $9.57B, up 11.8% from the year before. Over ten years it grew 12.4% a year on average. The highest annual figure on record is $10.53B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.57B | +11.8% |
| FY2024 | Dec 31, 2024 | $8.56B | +17.9% |
| FY2023 | Dec 31, 2023 | $7.26B | -24.2% |
| FY2022 | Dec 31, 2022 | $9.58B | -9.0% |
| FY2021 | Dec 31, 2021 | $10.53B | +33.3% |
| FY2020 | Dec 31, 2020 | $7.90B | +28.8% |
| FY2019 | Dec 31, 2019 | $6.14B | -2.6% |
| FY2018 | Dec 31, 2018 | $6.30B | +13.1% |
| FY2017 | Dec 31, 2017 | $5.57B | +73.9% |
| FY2016 | Dec 31, 2016 | $3.20B | +8.0% |
| FY2015 | Dec 31, 2015 | $2.97B | -19.3% |
| FY2014 | Dec 31, 2014 | $3.68B | +10.6% |
| FY2013 | Dec 31, 2013 | $3.32B | -64.3% |
| FY2012 | Dec 31, 2012 | $9.31B | +3.8% |
| FY2011 | Dec 31, 2011 | $8.97B | +2.7% |
| FY2010 | Dec 31, 2010 | $8.74B | +20.1% |
| FY2009 | Dec 31, 2009 | $7.28B | +4.0% |
| FY2008 | Dec 31, 2008 | $6.99B | +34.9% |
| FY2007 | Dec 31, 2007 | $5.18B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.49B | +21.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.32B | -7.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.32B | +15.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.79B | +3.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.05B | +4.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.42B | +38.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.87B | -5.6% |
| Q3 FY2024 | Sep 30, 2024 | $2.71B | +44.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.96B | +62.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.03B | -10.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.04B | +30.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.88B | -32.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.20B | -50.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.14B | -44.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.33B | -24.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.78B | +2.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.41B | +13.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.07B | -21.7% |
| Q4 FY2021 | Dec 31, 2021 | $3.07B | -19.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.70B | +30.7% |
| Q2 FY2021 | Jun 30, 2021 | $2.13B | +61.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.64B | +268.8% |
| Q4 FY2020 | Dec 31, 2020 | $3.80B | +57.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.07B | +6.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.32B | +24.7% |
| Q1 FY2020 | Mar 31, 2020 | $715.00M | +0.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.42B | +36.9% |
| Q3 FY2019 | Sep 30, 2019 | $1.95B | -10.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.06B | -14.8% |
| Q1 FY2019 | Mar 31, 2019 | $712.00M | -35.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.77B | +7.6% |
| Q3 FY2018 | Sep 30, 2018 | $2.18B | +8.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.24B | -7.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.11B | +93.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.64B | +40.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.01B | +64.7% |
| Q2 FY2017 | Jun 30, 2017 | $1.35B | – |
| Q1 FY2017 | Mar 31, 2017 | $574.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.17B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.22B | – |
See a number that looks wrong?